ANI Pharmaceuticals Inc (ANIP) 62.69 $ANIP
A Detailed Look At Why ANI Pharmaceuticals Should Outperform Short Term And Long Term.
Just the Facts Maam - at Seeking Alpha - Thu Feb 12, 10:34AM CST
ANIP: 62.69 (-0.43), ABBV: 58.05 (+1.00)
ANI Pharmaceuticals Schedules Conference Call for Fourth Quarter and Full Year 2014 Financial Results
PR Newswire - Thu Feb 12, 7:30AM CST
ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) announced today that the Company plans to release its fourth quarter and full year 2014 financial results on Thursday, February 19, 2015, before the opening of the U.S. financial markets. The earnings press release will be accessible through the Investor Relations section of the Company's website, www.anipharmaceuticals.com.
ANIP: 62.69 (-0.43)
4 Big-Volume Stocks to Trade for Breakouts: TrueBlue, K2M and More
at The Street - Mon Feb 09, 12:33PM CST
These stocks rising on unusual volume are within range of triggering breakout trades.
TBI: 22.79 (+0.08), ANIP: 62.69 (-0.43), SBGI: 26.55 (+0.87), KTWO: 19.75 (+0.01)
Seeking Alpha's Biotech Weekly: Intercept Pops, Provenge's Prince Valeant, And More
SA Editor Mike Taylor - at Seeking Alpha - Fri Jan 30, 3:00PM CST
BCRX: 10.06 (-0.09), ACT: 285.37 (+3.71), VRX: 167.00 (-0.50), PCYC: 163.28 (+0.23), ZSPH: 46.77 (+3.42), RMTI: 11.17 (+0.15), BCLI: 3.86 (-0.02), SIEN: 15.90 (+0.38), JNJ: 99.62 (+1.18), ECYT: 5.26 (-0.02), SNY: 49.42 (+0.82), LENS: 6.00 (-0.67), REGN: 402.40 (+0.66), SYK: 94.51 (+1.14), PFE: 34.64 (-0.23), SLXP: 152.35 (+3.17), AMGN: 153.48 (+0.30), APPY: 0.45 (-0.01), MNKD: 7.00 (+0.02), CELG: 115.88 (+0.16), ISRG: 510.73 (+3.02), GILD: 101.90 (+1.10), ANIP: 62.69 (-0.43), MRK: 58.81 (-0.07), ALXN: 182.29 (+6.02), CCXI: 7.85 (+0.04), ICPT: 209.12 (+7.12), AEZS: 0.53 (unch), ATRS: 2.45 (+0.05), NASH: 31.48 (+0.01)
ANI Pharmaceuticals Announces the Launch of Etodolac 300mg Capsules
PR Newswire - Fri Jan 30, 7:30AM CST
ANI Pharmaceuticals, Inc. ("ANI"
(NASDAQ: ANIP) today announced the launch of Etodolac 300mg oral capsules, indicated for use in the management of the signs and symptoms of osteoarthritis, rheumatoid arthritis, and acute pain. The US market for Etodolac 300mg capsules totals $9 million on a trailing 12 month basis, per IMS Health. Prior to today's announcement, only two companies marketed the product.
ANIP: 62.69 (-0.43)
Nasdaq stocks posting largest percentage increases
AP - Thu Jan 29, 12:23PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
UIHC: 27.40 (-0.34), ABMD: 60.39 (+0.46), ACAT: 39.00 (+1.31), CSII: 35.69 (+0.17), EA: 56.39 (+0.20), NVC.TO: 11.27 (-0.23), ARKR: 24.52 (-0.04), OMER: 20.63 (+0.13), RESN: 16.62 (-1.38), ICEL: 5.27 (+0.02), ANIP: 62.69 (-0.43), JST: 5.35 (+0.14), ADVS: 44.18 (+0.20), AAPL: 127.08 (+0.62), NVCN: 9.08 (-0.17)
Strong And Under The Radar Today: ANI Pharmaceuticals (ANIP)
at The Street - Wed Jan 28, 8:45AM CST
Trade-Ideas LLC identified ANI Pharmaceuticals (ANIP) as a strong and under the radar candidate
ANIP: 62.69 (-0.43)
Akorn Set to Join the S&P MidCap 400; United Insurance Holdings, ANI Pharmaceuticals to Join the S&P SmallCap 600
PR Newswire - Tue Jan 27, 4:46PM CST
S&P Dow Jones Indices will make the following changes to the S&P MidCap 400 and S&P SmallCap 600 indices:
KND: 19.68 (-0.38), UIHC: 27.40 (-0.34), PL: 69.95 (-0.01), ANIP: 62.69 (-0.43), AKRX: 47.28 (-0.25), MHFI: 102.19 (unch), GTIV: 19.19 (-0.23)
Why ANI Pharmaceuticals Is A Strong Buy
ONeil Trader - at Seeking Alpha - Tue Jan 27, 9:56AM CST
ANIP: 62.69 (-0.43)
2015 Stock Picks: 19 Out Of 300
Dark-Liquidity - at Seeking Alpha - Tue Jan 06, 6:59AM CST
GD: 137.61 (-0.54), SPTN: 25.99 (+0.14), VMW: 84.68 (+1.06), CACC: 172.65 (-2.73), DAL: 44.50 (-0.31), LKQ: 27.22 (+0.10), PCP: 205.54 (+1.37), GIB: 41.90 (+0.05), LUV: 43.30 (-0.20), SWK: 98.20 (+0.92), SPY: 209.78 (+0.86), QQQ: 106.91 (+0.91), MRVL: 16.59 (+0.08), GILD: 101.90 (+1.10), ANIP: 62.69 (-0.43), CNI: 70.04 (-0.39), RHT: 68.47 (+0.57), FFIV: 116.64 (+1.37), BSFT: 27.58 (+0.14), FL: 53.96 (-0.13), CTSH: 60.23 (-0.05), CBS: 59.83 (+2.06)
AMAG, Takeda Mutually End Agreement for Feraheme - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 30, 5:30PM CST
AMAG Pharmaceuticals (AMAG) and Takeda (TKPYY) mutually terminate their licensing deal for Ferahame in the ex-U.S. territories including Europe.
ANIP: 62.69 (-0.43), AMAG: 41.49 (+0.23), ACOR: 36.14 (-0.51)
BioMarin's Vimizim OK'd in Japan for Morquio A Syndrome - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 30, 4:10PM CST
BioMarin's (BMRN) Vimizim gained Japanese approval for the treatment of patients suffering from mucopolysaccharidosis type IVA or Morquio A syndrome.
BMRN: 100.76 (+1.98), RNA: 18.65 (unch), ANIP: 62.69 (-0.43), ACOR: 36.14 (-0.51)
Xenon Pharmaceuticals (XENE) Jumps: Stock Surges 16.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Dec 30, 8:11AM CST
Xenon Pharmaceuticals Inc. (XENE) was a big mover last session, as the company saw its shares rise by nearly 17% on the day.
ANIP: 62.69 (-0.43), XENE: 16.37 (+0.17)
Commit To Buy ANI Pharmaceuticals At $50, Earn 21.5% Annualized Using Options
at The Street - Mon Dec 29, 10:35AM CST
Investors eyeing a purchase of ANI Pharmaceuticals, Inc. stock, but tentative about paying the going market price of $54.69/share, might benefit from considering selling puts among the alternative strategies at their disposal.
ANIP: 62.69 (-0.43)
Actelion Submits New Drug Application for Uptravi in the U.S. - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 23, 4:35PM CST
Actelion Ltd. (ALIOF) announced the submission of a new drug application to the FDA for its pulmonary arterial hypertension candidate, Uptravi (selexipag).
ANIP: 62.69 (-0.43), UTHR: 151.11 (+3.59)
Stryker & Osiris Team Up to Market Viable Bone Matrix - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 23, 2:50PM CST
Under the partnership, Stryker Corporation (SYK) will attain exclusive, worldwide rights to Osiris' viable bone matrix under the name BIO4.
ANIP: 62.69 (-0.43), OSIR: 15.95 (+0.28), AFFX: 11.45 (+0.02), SYK: 94.51 (+1.14)
Will myRisk Cancer Test Work Wonders for Myriad Genetics? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 23, 1:30PM CST
During the reported quarter,Myriad Genetics (MYGN) experienced heightened physician demand for the myRisk test.
CYTK: 7.78 (+1.29), MYGN: 34.03 (+0.40), ANIP: 62.69 (-0.43), AFFX: 11.45 (+0.02)
Genomic Health (GHDX) Shines on Prospective Cancer Tests - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Dec 22, 4:50PM CST
Genomic Health (GHDX) strongly believes that its Oncotype DX prostate cancer test will strengthen its advanced next generation sequencing (NGS) platform and accelerate the development of future tests.
BIIB: 391.66 (-0.45), ANIP: 62.69 (-0.43), AFFX: 11.45 (+0.02), GHDX: 31.12 (+0.28)
Integra Lifesciences Up on Launch of Bilayer Skin Product - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Dec 19, 12:40PM CST
This latest single-use skin product of Integra (IART) is at present the only pre-meshed bilayer matrix that has been approved by the FDA to treat patients with third-degree burns and the subsequent scar contracture.
BIIB: 391.66 (-0.45), IART: 56.89 (+0.62), ANIP: 62.69 (-0.43), AFFX: 11.45 (+0.02)
Bruker Unveils bioAFM System for High Resolution Imaging - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Dec 18, 1:40PM CST
Bruker's (BRKR) BioScope Resolve provides real-time correlation of atomic force microscopy and optical microscopy data sets
BIIB: 391.66 (-0.45), ANIP: 62.69 (-0.43), BRKR: 18.77 (-0.02), AFFX: 11.45 (+0.02)
A Detailed Look At Why ANI Pharmaceuticals Should Outperform Short Term And Long Term.
Just the Facts Maam - at Seeking Alpha - Thu Feb 12, 10:34AM CST
ANIP: 62.69 (-0.43), ABBV: 58.05 (+1.00)
ANI Pharmaceuticals Schedules Conference Call for Fourth Quarter and Full Year 2014 Financial Results
PR Newswire - Thu Feb 12, 7:30AM CST
ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) announced today that the Company plans to release its fourth quarter and full year 2014 financial results on Thursday, February 19, 2015, before the opening of the U.S. financial markets. The earnings press release will be accessible through the Investor Relations section of the Company's website, www.anipharmaceuticals.com.
ANIP: 62.69 (-0.43)
4 Big-Volume Stocks to Trade for Breakouts: TrueBlue, K2M and More
at The Street - Mon Feb 09, 12:33PM CST
These stocks rising on unusual volume are within range of triggering breakout trades.
TBI: 22.79 (+0.08), ANIP: 62.69 (-0.43), SBGI: 26.55 (+0.87), KTWO: 19.75 (+0.01)
Seeking Alpha's Biotech Weekly: Intercept Pops, Provenge's Prince Valeant, And More
SA Editor Mike Taylor - at Seeking Alpha - Fri Jan 30, 3:00PM CST
BCRX: 10.06 (-0.09), ACT: 285.37 (+3.71), VRX: 167.00 (-0.50), PCYC: 163.28 (+0.23), ZSPH: 46.77 (+3.42), RMTI: 11.17 (+0.15), BCLI: 3.86 (-0.02), SIEN: 15.90 (+0.38), JNJ: 99.62 (+1.18), ECYT: 5.26 (-0.02), SNY: 49.42 (+0.82), LENS: 6.00 (-0.67), REGN: 402.40 (+0.66), SYK: 94.51 (+1.14), PFE: 34.64 (-0.23), SLXP: 152.35 (+3.17), AMGN: 153.48 (+0.30), APPY: 0.45 (-0.01), MNKD: 7.00 (+0.02), CELG: 115.88 (+0.16), ISRG: 510.73 (+3.02), GILD: 101.90 (+1.10), ANIP: 62.69 (-0.43), MRK: 58.81 (-0.07), ALXN: 182.29 (+6.02), CCXI: 7.85 (+0.04), ICPT: 209.12 (+7.12), AEZS: 0.53 (unch), ATRS: 2.45 (+0.05), NASH: 31.48 (+0.01)
ANI Pharmaceuticals Announces the Launch of Etodolac 300mg Capsules
PR Newswire - Fri Jan 30, 7:30AM CST
ANI Pharmaceuticals, Inc. ("ANI"
(NASDAQ: ANIP) today announced the launch of Etodolac 300mg oral capsules, indicated for use in the management of the signs and symptoms of osteoarthritis, rheumatoid arthritis, and acute pain. The US market for Etodolac 300mg capsules totals $9 million on a trailing 12 month basis, per IMS Health. Prior to today's announcement, only two companies marketed the product. ANIP: 62.69 (-0.43)
Nasdaq stocks posting largest percentage increases
AP - Thu Jan 29, 12:23PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
UIHC: 27.40 (-0.34), ABMD: 60.39 (+0.46), ACAT: 39.00 (+1.31), CSII: 35.69 (+0.17), EA: 56.39 (+0.20), NVC.TO: 11.27 (-0.23), ARKR: 24.52 (-0.04), OMER: 20.63 (+0.13), RESN: 16.62 (-1.38), ICEL: 5.27 (+0.02), ANIP: 62.69 (-0.43), JST: 5.35 (+0.14), ADVS: 44.18 (+0.20), AAPL: 127.08 (+0.62), NVCN: 9.08 (-0.17)
Strong And Under The Radar Today: ANI Pharmaceuticals (ANIP)
at The Street - Wed Jan 28, 8:45AM CST
Trade-Ideas LLC identified ANI Pharmaceuticals (ANIP) as a strong and under the radar candidate
ANIP: 62.69 (-0.43)
Akorn Set to Join the S&P MidCap 400; United Insurance Holdings, ANI Pharmaceuticals to Join the S&P SmallCap 600
PR Newswire - Tue Jan 27, 4:46PM CST
S&P Dow Jones Indices will make the following changes to the S&P MidCap 400 and S&P SmallCap 600 indices:
KND: 19.68 (-0.38), UIHC: 27.40 (-0.34), PL: 69.95 (-0.01), ANIP: 62.69 (-0.43), AKRX: 47.28 (-0.25), MHFI: 102.19 (unch), GTIV: 19.19 (-0.23)
Why ANI Pharmaceuticals Is A Strong Buy
ONeil Trader - at Seeking Alpha - Tue Jan 27, 9:56AM CST
ANIP: 62.69 (-0.43)
2015 Stock Picks: 19 Out Of 300
Dark-Liquidity - at Seeking Alpha - Tue Jan 06, 6:59AM CST
GD: 137.61 (-0.54), SPTN: 25.99 (+0.14), VMW: 84.68 (+1.06), CACC: 172.65 (-2.73), DAL: 44.50 (-0.31), LKQ: 27.22 (+0.10), PCP: 205.54 (+1.37), GIB: 41.90 (+0.05), LUV: 43.30 (-0.20), SWK: 98.20 (+0.92), SPY: 209.78 (+0.86), QQQ: 106.91 (+0.91), MRVL: 16.59 (+0.08), GILD: 101.90 (+1.10), ANIP: 62.69 (-0.43), CNI: 70.04 (-0.39), RHT: 68.47 (+0.57), FFIV: 116.64 (+1.37), BSFT: 27.58 (+0.14), FL: 53.96 (-0.13), CTSH: 60.23 (-0.05), CBS: 59.83 (+2.06)
AMAG, Takeda Mutually End Agreement for Feraheme - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 30, 5:30PM CST
AMAG Pharmaceuticals (AMAG) and Takeda (TKPYY) mutually terminate their licensing deal for Ferahame in the ex-U.S. territories including Europe.
ANIP: 62.69 (-0.43), AMAG: 41.49 (+0.23), ACOR: 36.14 (-0.51)
BioMarin's Vimizim OK'd in Japan for Morquio A Syndrome - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 30, 4:10PM CST
BioMarin's (BMRN) Vimizim gained Japanese approval for the treatment of patients suffering from mucopolysaccharidosis type IVA or Morquio A syndrome.
BMRN: 100.76 (+1.98), RNA: 18.65 (unch), ANIP: 62.69 (-0.43), ACOR: 36.14 (-0.51)
Xenon Pharmaceuticals (XENE) Jumps: Stock Surges 16.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Dec 30, 8:11AM CST
Xenon Pharmaceuticals Inc. (XENE) was a big mover last session, as the company saw its shares rise by nearly 17% on the day.
ANIP: 62.69 (-0.43), XENE: 16.37 (+0.17)
Commit To Buy ANI Pharmaceuticals At $50, Earn 21.5% Annualized Using Options
at The Street - Mon Dec 29, 10:35AM CST
Investors eyeing a purchase of ANI Pharmaceuticals, Inc. stock, but tentative about paying the going market price of $54.69/share, might benefit from considering selling puts among the alternative strategies at their disposal.
ANIP: 62.69 (-0.43)
Actelion Submits New Drug Application for Uptravi in the U.S. - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 23, 4:35PM CST
Actelion Ltd. (ALIOF) announced the submission of a new drug application to the FDA for its pulmonary arterial hypertension candidate, Uptravi (selexipag).
ANIP: 62.69 (-0.43), UTHR: 151.11 (+3.59)
Stryker & Osiris Team Up to Market Viable Bone Matrix - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 23, 2:50PM CST
Under the partnership, Stryker Corporation (SYK) will attain exclusive, worldwide rights to Osiris' viable bone matrix under the name BIO4.
ANIP: 62.69 (-0.43), OSIR: 15.95 (+0.28), AFFX: 11.45 (+0.02), SYK: 94.51 (+1.14)
Will myRisk Cancer Test Work Wonders for Myriad Genetics? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 23, 1:30PM CST
During the reported quarter,Myriad Genetics (MYGN) experienced heightened physician demand for the myRisk test.
CYTK: 7.78 (+1.29), MYGN: 34.03 (+0.40), ANIP: 62.69 (-0.43), AFFX: 11.45 (+0.02)
Genomic Health (GHDX) Shines on Prospective Cancer Tests - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Dec 22, 4:50PM CST
Genomic Health (GHDX) strongly believes that its Oncotype DX prostate cancer test will strengthen its advanced next generation sequencing (NGS) platform and accelerate the development of future tests.
BIIB: 391.66 (-0.45), ANIP: 62.69 (-0.43), AFFX: 11.45 (+0.02), GHDX: 31.12 (+0.28)
Integra Lifesciences Up on Launch of Bilayer Skin Product - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Dec 19, 12:40PM CST
This latest single-use skin product of Integra (IART) is at present the only pre-meshed bilayer matrix that has been approved by the FDA to treat patients with third-degree burns and the subsequent scar contracture.
BIIB: 391.66 (-0.45), IART: 56.89 (+0.62), ANIP: 62.69 (-0.43), AFFX: 11.45 (+0.02)
Bruker Unveils bioAFM System for High Resolution Imaging - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Dec 18, 1:40PM CST
Bruker's (BRKR) BioScope Resolve provides real-time correlation of atomic force microscopy and optical microscopy data sets
BIIB: 391.66 (-0.45), ANIP: 62.69 (-0.43), BRKR: 18.77 (-0.02), AFFX: 11.45 (+0.02)
